Osterweis Capital Management’s NEVRO CORP. NVRO Stock Holding History

Osterweis Capital Management’s Portfolio NVRO Stock Details NVRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-27,519	Closed	-$2.58M	–	106
2017 Q1	$2.58M	Sell	27,519 -2,865	-9%	-$260K	0.2%	60
2016 Q4	$2.21M	Buy	30,384 +16,364	+117%	+$1.4M	0.16%	60
2016 Q3	$1.46M	Sell	14,020 -14,000	-50%	-$1.26M	0.09%	67
2016 Q2	$2.07M	Buy	+28,020	New	+$1.9M	0.13%	48

Other funds holding NVRO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Osterweis Capital Management's NVRO Position: Q2 2017 in Review

Osterweis Capital Management sold out of NEVRO CORP. (NVRO) in Q2 2017, closing a stake of 27,519 shares — an estimated $2.58M sold.

Osterweis Capital Management first reported a position in NVRO in Q2 2016 and held it in 4 quarters. The position peaked at $2.58M in Q1 2017. 201 funds tracked by Wall St. Rank hold NVRO as of Q2 2017.

Osterweis Capital Management reported no remaining NEVRO CORP. position as of Q2 2017 after selling out during the quarter.
Osterweis Capital Management sold 27,519 NEVRO CORP. shares in Q2 2017, an estimated $2.58M.
Osterweis Capital Management first reported a position in NEVRO CORP. in Q2 2016 and held it in 4 quarters.
Osterweis Capital Management's NEVRO CORP. position peaked at $2.58M in Q1 2017.
201 funds tracked by Wall St. Rank held NEVRO CORP. as of Q2 2017.

Based on Osterweis Capital Management's 13F filing for Q2 2017, filed 15 Aug 2017.